Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01629615 · ClinicalTrials.gov registry record · Phase 2
A Trial of BKM120 (a PI3K Inhibitor) in Patients With Triple Negative Metastatic Breast Cancer
A Phase 2 study, sponsored by SOLTI Breast Cancer Research Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
NCT01629615 is a Phase 2 study that has completed, run by SOLTI Breast Cancer Research Group. The registered enrollment target is 50 participants.
The verdict
NCT01629615, a Phase 2 study, has completed, sponsored by SOLTI Breast Cancer Research Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the clinical activity of BKM120 in patients with metastatic triple-negative breast cancer.
Interventions
- DRUG BKM120
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2012-06 |
| Est. Completion | 2015-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01629615
The ClinicalTrials.gov registry entry for NCT01629615 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SOLTI Breast Cancer Research Group, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BKM120 is the first listed.
NCT01629615 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01629615 about?
NCT01629615 is a clinical study titled "A Trial of BKM120 (a PI3K Inhibitor) in Patients With Triple Negative Metastatic Breast Cancer". The purpose of this study is to evaluate the clinical activity of BKM120 in patients with metastatic triple-negative breast cancer.
What is the current status of trial NCT01629615?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2012-06. Estimated completion is 2015-10.
What interventions are being tested in trial NCT01629615?
The interventions under investigation include: BKM120 (DRUG).
Who is sponsoring clinical trial NCT01629615?
This trial is sponsored by SOLTI Breast Cancer Research Group, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.